Synairgen plc Synairgen Notice of Interim Results (3783M)

TIDMSNG

RNS Number : 3783M

Synairgen plc

21 September 2021

Press release

Synairgen plc

('Synairgen' or the 'Company')

Notice of Interim Results

Southampton, UK - 21 September 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, will announce its unaudited half-year report for the six months ended 30 June 2021 on Thursday 30 September 2021.

A webcast and Q&A session for analysts will be hosted by Synairgen's management team at 13:00 BST on 30 September 2021. Analysts should contact Consilium Strategic Communications for further details on [e-mail] .

A recording of the webcast will be made available via the Investors section of the Company's website at

www.synairgen.com   later in the day. 

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

[e-mail]

Tel: [phone]

MKC Strategies, LLC (US Media Relations)

Mary Conway

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory biotechnology company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration (FDA) and deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR), Synairgen's Phase III clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase II trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to 'no limitation of activities' versus placebo.

Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREAPNEAAEFEFA

(END) Dow Jones Newswires

September 21, 2021 02:00 ET (06:00 GMT)